Q4 EPS Estimates for DENTSPLY SIRONA Decreased by Analyst

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Stock analysts at Zacks Research decreased their Q4 2024 earnings per share (EPS) estimates for shares of DENTSPLY SIRONA in a note issued to investors on Thursday, November 28th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will earn $0.45 per share for the quarter, down from their previous forecast of $0.58. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.84 per share. Zacks Research also issued estimates for DENTSPLY SIRONA’s Q1 2025 earnings at $0.42 EPS, Q2 2025 earnings at $0.51 EPS, Q3 2025 earnings at $0.50 EPS, Q4 2025 earnings at $0.54 EPS, FY2025 earnings at $1.97 EPS, Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.55 EPS and Q3 2026 earnings at $0.53 EPS.

Other analysts have also issued research reports about the company. StockNews.com lowered DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research report on Tuesday, November 19th. Barrington Research cut their price objective on DENTSPLY SIRONA from $36.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. Leerink Partnrs lowered DENTSPLY SIRONA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 7th. Needham & Company LLC dropped their target price on DENTSPLY SIRONA from $34.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Finally, Robert W. Baird cut their price target on shares of DENTSPLY SIRONA from $31.00 to $24.00 and set a “neutral” rating on the stock in a research note on Friday, November 8th. Seven analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $29.50.

DENTSPLY SIRONA Stock Performance

Shares of XRAY stock opened at $19.65 on Monday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.84 and a current ratio of 1.25. The firm has a market cap of $3.91 billion, a P/E ratio of -9.49, a P/E/G ratio of 1.93 and a beta of 1.02. The firm’s 50 day moving average price is $22.55 and its 200-day moving average price is $24.74. DENTSPLY SIRONA has a one year low of $17.21 and a one year high of $37.60.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.02. DENTSPLY SIRONA had a negative net margin of 10.59% and a positive return on equity of 12.62%. The company had revenue of $951.00 million for the quarter, compared to analysts’ expectations of $939.10 million. During the same quarter in the prior year, the company posted $0.49 earnings per share. DENTSPLY SIRONA’s revenue for the quarter was up .4% compared to the same quarter last year.

Hedge Funds Weigh In On DENTSPLY SIRONA

Institutional investors and hedge funds have recently made changes to their positions in the stock. First Eagle Investment Management LLC lifted its stake in DENTSPLY SIRONA by 33.6% in the second quarter. First Eagle Investment Management LLC now owns 13,069,900 shares of the medical instruments supplier’s stock worth $325,571,000 after acquiring an additional 3,283,965 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in DENTSPLY SIRONA by 42.0% during the second quarter. Dimensional Fund Advisors LP now owns 4,420,445 shares of the medical instruments supplier’s stock worth $110,118,000 after purchasing an additional 1,308,411 shares in the last quarter. Cooke & Bieler LP lifted its position in shares of DENTSPLY SIRONA by 16.2% during the 2nd quarter. Cooke & Bieler LP now owns 7,506,845 shares of the medical instruments supplier’s stock worth $186,996,000 after buying an additional 1,046,105 shares during the last quarter. Invenomic Capital Management LP acquired a new position in shares of DENTSPLY SIRONA in the 3rd quarter valued at $23,724,000. Finally, National Bank of Canada FI grew its position in shares of DENTSPLY SIRONA by 684.6% in the 2nd quarter. National Bank of Canada FI now owns 876,400 shares of the medical instruments supplier’s stock valued at $21,586,000 after buying an additional 764,700 shares during the last quarter. 95.70% of the stock is owned by institutional investors and hedge funds.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.